Relmada Therapeutics Inc. (RLMD) Financial Statements (2024 and earlier)

Company Profile

Business Address 2222 PONCE DE LEON BLVD. 3RD FLOOR
CORAL GABLES, FL 33134
State of Incorp. NV
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments96,324106,267118,529132,442148,323184,152
Cash and cash equivalents4,0926,69914,46928,8945,39642,524
Short-term investments92,23299,569104,060103,548142,927141,628
Receivables     512 
Prepaid expense1,1852,8343,4753,0904,0352,954
Total current assets:97,509109,101122,004135,532152,870187,106
Noncurrent Assets
Other noncurrent assets434835353516
Total noncurrent assets:434835353516
TOTAL ASSETS:97,552109,149122,038135,566152,905187,122
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities12,1958,42210,70210,09712,46921,425
Employee-related liabilities648
Accounts payable3,5062,8574,8544,4225,26210,426
Accrued liabilities8,6895,5655,8495,6757,20710,351
Other undisclosed current liabilities      (648)
Total current liabilities:12,1958,42210,70210,09712,46920,777
Noncurrent Liabilities
Total liabilities:12,1958,42210,70210,09712,46920,777
Equity
Equity, attributable to parent85,357100,727111,336125,469140,436166,345
Common stock303030303029
Additional paid in capital646,230636,434625,041613,872602,517590,483
Accumulated deficit(560,903)(535,738)(513,735)(488,433)(462,111)(424,167)
Total equity:85,357100,727111,336125,469140,436166,345
TOTAL LIABILITIES AND EQUITY:97,552109,149122,038135,566152,905187,122

Income Statement (P&L) ($ in thousands)

3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
Revenues      
Realized investment gains (losses)(3,346)(52) (667)(33)(562)
Cost of revenue
(Cost of Goods and Services Sold)
    (180)  
Gross profit:   (180)  
Operating expenses(26,829)(22,693)(26,027)(28,154)(38,702)(38,737)
Other undisclosed operating income (loss) 52 180 562
Operating loss:(26,829)(22,693)(26,027)(28,154)(38,702)(38,737)
Nonoperating income (expense)1,6646917241,832758(682)
Investment income, nonoperating      
Other undisclosed income from continuing operations before equity method investments, income taxes     6,352 
Loss from continuing operations:(25,165)(22,002)(25,303)(26,322)(31,593)(39,419)
Loss before gain (loss) on sale of properties:(39,419)
Net loss:(25,165)(22,002)(25,303)(26,322)(31,593)(39,419)
Other undisclosed net loss attributable to parent     (6,352) 
Net loss available to common stockholders, diluted:(25,165)(22,002)(25,303)(26,322)(37,944)(39,419)

Comprehensive Income ($ in thousands)

3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
Net loss:(25,165)(22,002)(25,303)(26,322)(31,593)(39,419)
Comprehensive loss, net of tax, attributable to parent:(25,165)(22,002)(25,303)(26,322)(31,593)(39,419)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: